• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Centessa Pharmaceuticals Plc ADR (NQ: CNTA )

    9.610 +0.070 (+0.73%)
    Streaming Delayed Price Updated: 9:44 AM EDT, Jul 16, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 52,463
    Open 9.600
    Bid (Size) 9.610 (1)
    Ask (Size) 9.770 (4)
    Prev. Close 9.540
    Today's Range 9.540 - 9.820
    52wk Range 5.150 - 12.45
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as Chief Financial Officer and Gregory Weinhoff MD MBA, as Chief Business Officer
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire

    Performance

    YTD
    +19.68%
    +19.68%
    1 Month
    +0.84%
    +0.84%
    3 Month
    -10.85%
    -10.85%
    6 Month
    +31.64%
    +31.64%
    1 Year
    +21.19%
    +21.19%

    More News

    Read More
    CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q1 2024
    Via InvestorPlace
    Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    CNTA Stock Earnings: Centessa Pharmaceuticals Beats EPS for Q4 2023
    Via InvestorPlace
    Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    7 Biotech Stocks Ready to Ride the Sector’s Resurgence
    Via InvestorPlace
    Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
    From AnaptysBio, Inc.
    Via GlobeNewswire
    Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
    From Centessa Pharmaceuticals plc
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.